Ivana Peran
Overview
Explore the profile of Ivana Peran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malchiodi Z, Suter R, Deshpande A, Peran I, Harris B, Duttargi A, et al.
bioRxiv
. 2024 Jun;
PMID: 38853982
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer. PDAC's poor prognosis and resistance to immunotherapy are attributed in part to its dense, fibrotic tumor microenvironment...
2.
Sebastian A, Martin K, Peran I, Hum N, Leon N, Amiri B, et al.
Front Oncol
. 2023 Nov;
13:1286861.
PMID: 37954069
Pancreatic ductal adenocarcinoma (PDAC) is one of the top five deadliest forms of cancer with very few treatment options. The 5-year survival rate for PDAC is 10% following diagnosis. Cadherin...
3.
da Cruz R, Dominguez O, Chen E, Gonsiewski A, Nasir A, Cruz M, et al.
Res Sq
. 2023 Feb;
PMID: 36798383
DNA sequence accounts for the majority of disease heritability, including cancer. Yet, not all familial cancer cases can be explained by genetic factors. It is becoming clear that environmentally induced...
4.
Peran I, Vietsch E, Yan G, Riegel A, Wellstein A
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326668
Pancreatic adenocarcinoma is typically detected at a late stage and thus shows only limited sensitivity to treatment, making it one of the deadliest malignancies. In this study, we evaluate changes...
5.
Issa N, Wathieu H, Glasgow E, Peran I, Parasido E, Li T, et al.
Ecotoxicol Environ Saf
. 2022 Feb;
233:113330.
PMID: 35189517
Environmental chemical (EC) exposures and our interactions with them has significantly increased in the recent decades. Toxicity associated biological characterization of these chemicals is challenging and inefficient, even with available...
6.
Vietsch E, Peran I, Suker M, van den Bosch T, van der Sijde F, Kros J, et al.
Appl Sci (Basel)
. 2021 Sep;
9(22).
PMID: 34484811
Clinical follow-up aided by changes in the expression of circulating microRNAs (miRs) may improve prognostication of pancreatic ductal adenocarcinoma (PDAC) patients. Changes in 179 circulating miRs due to cancer progression...
7.
Peran I, Dakshanamurthy S, McCoy M, Mavropoulos A, Allo B, Sebastian A, et al.
Gastroenterology
. 2020 Dec;
160(4):1359-1372.e13.
PMID: 33307028
Background & Aims: Pancreatic ductal adenocarcinomas (PDACs) are characterized by fibrosis and an abundance of cancer-associated fibroblasts (CAFs). We investigated strategies to disrupt interactions among CAFs, the immune system, and...
8.
Sebastian A, Hum N, Martin K, Gilmore S, Peran I, Byers S, et al.
Cancers (Basel)
. 2020 May;
12(5).
PMID: 32455670
Cancer-associated fibroblasts (CAFs) are a prominent stromal cell type in solid tumors and molecules secreted by CAFs play an important role in tumor progression and metastasis. CAFs coexist as heterogeneous...
9.
Parasido E, Avetian G, Naeem A, Graham G, Pishvaian M, Glasgow E, et al.
Mol Cancer Res
. 2019 Jun;
17(9):1815-1827.
PMID: 31164413
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and, very often, ineffective medical and surgical therapeutic options. The treatment of patients with advanced unresectable PDAC is restricted...
10.
Peran I, Madhavan S, Byers S, McCoy M
Clin Cancer Res
. 2018 May;
24(16):3813-3819.
PMID: 29739787
Publicly available databases, for example, The Cancer Genome Atlas (TCGA), containing clinical and molecular data from many patients are useful in validating the contribution of particular genes to disease mechanisms...